

RESOURCES

PEOPLE

Guilford Pharmaceuticals (Baltimore, MD) has announced the appointment of **David H. Bergstrom** as vice president, pharmaceutical and chemical development. Dr. Bergstrom joins Guilford from Hoechst Marion Roussel, where for the past two years he was director of pharmaceutical and analytical sciences.



James Cappola has been appointed vice president, medical affairs at Cephalon (West Chester, PA). Dr. Cappola was most recently executive director, medical affairs, North American medical operations at Phoenix International Life Sciences. Cephalon also announced the promotions of **Colin Markland** to senior medical director, Europe; **John Dawson** to country manager/United Kingdom and senior director, finance, Europe; **John Mallamo** to vice president, drug discovery; **Craig Dionne** to vice president, oncology; **Richard Scott** to vice president, neurobiology; and **John Farah** to senior director, business development.

Myriad Genetics (Salt Lake City, UT) has announced the appointment of **Gregory Critchfield** as president of its wholly owned subsidiary, Myriad Genetic Laboratories. Dr. Critchfield previously served as senior vice president, chief medical and science officer of Quest Diagnostics (formerly Corning Clinical Laboratories). Also, Myriad has named **James S. Kuo** vice president of business development. Dr. Kuo previously served as president and CEO of Discovery Laboratories.

Michael R. Dougherty has been appointed president and CEO of Magainin Pharmaceuticals (Plymouth Meeting, PA). Most recently, he was executive vice president. Additionally, **Roy C. Levitt** has been named to the newly created position of chief operating officer, and **Zola P. Horovitz** has been named chairman of the board. Levitt joined Magainin in 1996 and most recently was head of research and development. Horovitz, formerly vice president of Bristol-Myers Squibb, joined Magainin's board in 1995. Jay Moorin, Magainin's former chairman, president, and chief executive, has resigned to pursue other interests. He will remain a consultant to the company.

T-Cell Sciences (Needham, MA) has announced the appointment of **Thomas R. Fuerst** as vice president of corporate development. Dr. Fuerst joins the company from Genetex, where he was cofounder, president, and director of research.



Aronex Pharmaceuticals (The Woodlands, TX) has appointed **Phyllis I. Gardner** to its board of directors, bringing its total to seven members. Dr. Gardner is the senior associate dean for education and student affairs at Stanford University School of Medicine.

Lidak Pharmaceuticals (San Diego, CA) has named **Gregory Hanson** its chief financial officer, replacing Jeffery Weinress, who recently resigned. Hanson was most recently chief financial officer of Xxsys Technologies.

Human Genome Sciences (Rockville, MD) has announced that **Daniel J. Odenheimer** has joined the company as director, medical affairs. Dr. Odenheimer most recently worked at British Biotech, where was director of US clinical research.

John P. Richard has been named executive vice president for business development at Sequus Pharmaceuticals (Menlo Park, CA). Mr. Richard joins Sequus from Vivus, where he served as vice president, corporate development. In addition, Sequus announced the promotion of **Joseph J. Vallner** to COO. Dr. Vallner joined the company in 1992.

Diversa (San Diego, CA) has announced that **Jay M. Short** has become president and chief technology officer. Dr. Short joined Diversa in 1994, and was formerly executive vice president and CTO. He is also a member of the board of directors.

George A. Vandeman, Amgen's (Thousand Oaks, CA) senior vice president, general counsel, and secretary, has been named to the additional post of senior vice president, corporate development, responsible for merger and acquisition activity. Vandeman previously headed the M&A practice at Latham & Watkins before joining Amgen in 1995. He succeeds Robert S. Attiyeh, who retired in June.

Cadus Pharmaceutical (Tarrytown, NY) has named **Charles Woler** president and chief executive. Most recently, Dr. Woler was general manager of Bouchara Group, responsible in particular for its pharmaceutical OTC division and for research and development.

PFANSTIEHL

The tools you need for oligosaccharide synthesis.

Our selectively blocked sugars can give you a head start on oligosaccharide synthesis. We offer a wide range of these key intermediates including thioglycosides, per-benzylated and acylated mono- & disaccharides, glycals, lactones, acetonide and benzylidene derivatives. If you have a specific compound you need to get started contact us today. Request information.

PFANSTIEHL LABORATORIES, INC. The source for carbohydrate chemistry

1219 Glen Rock Avenue / Waukegan, IL 60085-0439
847/623-0370 • Toll Free: 1-800/383-0126 • FAX: 847/623-9173

International: Pfanstiehl (Europe) Ltd.
+44 (0) 1606.331825 • FAX: +44 (0) 1606.331826

<http://www.pfanstiehl.com> e-mail: info@pfanstiehl.com



Pg

MAKING THINGS WORK